

## **The integrity of the antimicrobial supply chain in Bangladesh: assessing the regulatory environment and contextual challenges**

**Ebiowei S.F. Orubu<sup>1,4\*</sup>, Mohammed A. Samad<sup>2</sup>, Md. Tanvir Rahman<sup>3</sup>, Muhammad H. Zaman<sup>4</sup>, Veronika J. Wirtz<sup>5</sup>**

<sup>1</sup> Boston University Institute for Health System Innovation & Policy, Boston, USA;

sforubu@bu.edu

<sup>2</sup> Antimicrobial Resistance Action Centre, Bangladesh Livestock Research Institute (BLRI),

Savar, Dhaka-1341, Bangladesh ; samad\_blri@yahoo.co.nz

<sup>3</sup> Bangladesh Agricultural University, Department of Microbiology and Hygiene, Faculty of

Veterinary Science, Mymensingh-2202, Bangladesh; [tanvirahman@bau.edu.bd](mailto:tanvirahman@bau.edu.bd)

<sup>4</sup> Boston University College of Engineering, Department of Biomedical Engineering, Boston,

USA; zaman@bu.edu

<sup>5</sup> Boston University School of Public Health, Department of Global Health, Boston, USA;

vwirtz@bu.edu

\* Corresponding author: Email: sforubu@bu.edu

Key words: Antimicrobial, Supply Chain, Regulation, Quality

**Running Head: Antimicrobial supply chain integrity Bangladesh**

## **Abstract**

Poor-quality medicines lead to large individual, health systems and national economic losses. Most low- and middle-income countries (LMICs) lack the robust regulatory quality assurance system necessary to contain the spread of poor-quality medicines. Innovations in regulatory systems strengthening are needed to protect public health. In this study, we assessed the integrity of the antimicrobial supply chain in Bangladesh and suggest innovations. We employed a qualitative methodology comprising a policy content analysis, and literature and database reviews. Bangladesh was chosen as a model LMIC because of its pharmaceuticals production capacity. Using a framework modified from the World Health Organization's and the United States Pharmacopoeia's, the Bangladesh National Drug Policy (BNDP) was evaluated for provisions on quality assurance mechanisms that match regulatory functions. Newspaper, peer-reviewed and post-marketing surveillance reports were used to assess the extent of poor-quality antimicrobials in circulation. There are provisions for quality assurance in the BNDP. Newspaper reports identified the circulation of substandard antimicrobials and reported on actions by the government to seize fraudulent/falsified and expired products. Only six peer-review studies testing antimicrobial product quality were identified; the three studies with the larger sample size (over 10 samples tested) reported results of out-of-specifications products. This assessment found evidence of regulatory actions against poor-quality antimicrobials as well as news reports and studies suggesting quality concerns, but no current rigorous assessment of the extent in Bangladesh. We suggest a multi-pronged approach to regulatory system strengthening comprising three strategies: community-based surveillance, task-shifting, and technology-enabled consumer participation.

## Introduction

Maintaining the integrity of the pharmaceutical supply chain to prevent the entry of poor-quality medicines continues to be a regulatory challenge for many countries. In 1995, a report of fatal diethylene glycol poisoning following the administration of contaminated paracetamol syrup to children emerged from Bangladesh (1). This case echoed similar incidents in the late 1930s in the USA, contemporaneously in Nigeria and would go on to recur in other countries, most recently in February 2020 in India (2–6). In 2017, the global prevalence of Substandard and Falsified (SF) medicines was estimated at 10.5%; based on data from mostly Low- and Middle-Income Countries (LMICs) in Africa. In April 2020, supply chain disruptions induced by the recent COVID-19 led to a rise in the incidence of falsified chloroquine, one of the medicines with putative efficacy against SARS-Cov2, in the World Health Organization (WHO) regions of Africa and Europe. These examples illustrate the persistence and prevalence of the challenge to pharmaceutical supply chain integrity, especially in LMICs, and the need for effective, proactive, and continuous regulatory oversight to protect public health. For LMICs with capacity constraints, there is the need for innovative approaches to regulatory systems strengthening.

The WHO defines poor-quality medicines as those that are SF. A substandard medicine is one that is out-of-specification, or fails to meet quality checks, while a falsified medicine is one that deliberately misleads as to content, or manufacturer (7). The impacts of poor-quality medicines extend beyond the individual to health systems and economies (8). Poor-quality antimicrobials contribute to antimicrobial resistance (AMR) with transnational impacts, reinforcing the need for stringent regulatory controls to ensure product integrity in the supply chain (9,10).

In many countries, the duty of ensuring the quality of medicines in the supply chain rests with the national medicines regulatory authority (NMRA), which is a public body with the technical

and constitutional authority to provide an oversight function. However, most LMICs have limited regulatory capacity to perform all the functions necessary to protect the medicine supply chain against the entry of SF medicines (11). Current approaches to regulatory systems strengthening focus on improving capacity at the NMRA. However, the persistence of the problem of SF medicines in LMICs calls for further innovations in regulatory medicine quality assurance.

The aim of this study, as part of a broader Social Innovation on Drug Resistance program, was to assess the integrity of the antimicrobial supply chain in Bangladesh to understand the regulatory environment and contextual challenges. Understanding local contexts including the prevalence of SF medicines and gaps in regulatory approaches is important to any initiative to address challenges (12). While the WHO report gives a global prevalence of SF medicines, there are scant reports from other WHO geographical regions, including the WHO Southeast Asian region. Bangladesh, located in the WHO Southeast, has a large human and animal population and was selected as a model because of its pharmaceutical production capacity. The objectives were to: (i) evaluate the regulatory policies, and other mechanisms, for assuring the quality of antimicrobials in Bangladesh; (ii) identify any reports or publications on the prevalence of SF medicines.

## **Methods**

The study employed a qualitative methodology comprising document, literature, and database reviews to assess regulatory policies and any quality issues in the antimicrobial supply chain in Bangladesh.

**Policies:** We performed a document review by searching the website of the NMRA, the Directorate General of Drug Administration (DGDA), for policies and regulations governing the pharmaceutical supply chain in March 2020 (13).

To evaluate the policy, we modified the regulatory functions frameworks of the WHO and the United States Pharmacopoeia, USP (14,15) to construct a framework covering pre-marketing authorization to post-marketing surveillance mechanisms for oversight of the five tiers of the pharmaceutical supply chain (Table 1). This framework grouped regulatory mechanisms into four: current Good Manufacturing Practice (cGMP); Good Distribution Practices (GDP); Good Pharmacy Practice (GPP) guidelines; and pharmacovigilance. The four mechanisms comprised 10 functions.

The relevant sections of the policy document corresponding to these grouped functions were identified and described. Additionally, any other quality assurance mechanism specific for antimicrobials identified from practice experience or knowledge were noted and described.

Market surveillance and quality issues: To map reports and publications on SF medicines and market surveillance activities, we conducted a combined literature and database review as detailed:

1. Literature review for reports on SF medicines: To identify media reports of SF medicines in circulation/supply chain and/or market surveillance, we performed a literature search for grey literature (non-peer reviewed newspaper reports). Literature from 2017-2020 were reviewed. The literature search was conducted twice in December 2018 and April 2020. The search strategy and extracted data are described in the Appendix.

2. Publications on quality testing: A review of published literature was performed on *Banglajol* (an online service providing access to Bangladeshi Journals), EMBASE and Google Scholar to identify reports of quality evaluations of antimicrobials in circulation in Bangladesh. The literature search was conducted on May 18-19, 2020, as detailed in the Appendix.
3. Database reviews for post-marketing surveillance reports: Three databases – the United States Pharmacopoeia, USP, Medicine Quality Database (MQDB) (16), the Oxford’s Infectious Disease Data Observatory’s Medicine Quality Monitoring Globe database (MQMG) (17), and the DGDA database (18) – were searched for any records of quality issues with marketed antimicrobials in Bangladesh. Searches were conducted in May 2020. For the first two databases, a keyword search was performed using “Bangladesh”. Any report of a poor-quality medicine was noted. For the DGDA database, reports of any post-marketing surveillance were retrieved.

## **Results**

These results present a composite view of the regulatory environment (policies and post-marketing surveillance) and media and peer-reviewed reports and publications respectively on the quality of antimicrobials in the pharmaceutical supply chain in Bangladesh.

## **Policies**

Four documents laying out government’s policies for ensuring medicine quality in Bangladesh were identified as:

- Drug (Control) Ordinance 1982.
- The Drug (Control) (Amendment) Ordinance 1984.

- Drug Control Ordinance 2006 and
- National Drug Policy 2016 (13).

The National Drug Policy 2016 (NDP) is the current document guiding quality assurance throughout the supply chain, and builds upon previous versions starting from 1982, the first in independent Bangladesh. It codifies both the protectionism and supply chain medicine quality assurance mechanisms for Active Pharmaceutical Ingredients (API) and Finished Pharmaceutical Products (FPP) for use in human and animal health in Bangladesh and is aligned with the National Health Policy of 2011. This document recognizes poor-quality medicines as those that are: fake, adulterated, expired, unregistered, counterfeit, misbranded, smuggled, and substandard. We identified 10 mechanisms for the quality assurance of medicines in Bangladesh in the NDP covering all four pre-defined areas as well as a new provision for environmental protection against antimicrobial run-offs from manufacturing plants (Table 2).

### **Market surveillance and quality issues**

**Media reports:** Out of 200 listed reports in The Daily Star newspaper of Bangladesh, 27 met the inclusion criteria. Of these, 12 reports were on SF medicines. In three of these reports, antimicrobials were expressly mentioned, and these were evaluated (Table 3). Two of evaluated reports were on falsified antibiotics in private facilities, which were seized, and the perpetrators arrested and/or fined (19,20). In one case up to seven different antibiotics were falsified, with most (57%, 4/7) being cephalosporins (20). The third was on expired anthelmintic distributed to a public facility.

**Reports on medicine quality:** The search on Google Scholar retrieved six studies on the quality evaluation of antibiotics marketed in Bangladesh (Table 4). The EMBASE search retrieved three

studies already in the Google Scholar search results. No relevant publications were identified via *Banglajol*.

Overall, the six studies tested between 1-6 different antibiotics from different manufacturers; the smallest study tested 3 different generics and the largest 39, where studies with larger samples found more out-of-specification results. Importantly, Faruque (2018) et al testing 39 samples of six antibiotics – cefixime, cephradine, ciprofloxacin, metronidazole, amoxicillin, and azithromycin – found all six evaluated antibiotics to be falsified, with no API content for five, and a low out-of-specification content for azithromycin. This study also suggests that SF medicines may be more prevalent in rural areas (21). Uddin (2017) found that 40% (4/10) different ciprofloxacin brands tested did not meet the dissolution specifications in the USP (or 60%, when evaluated by the British Pharmacopeia, BP) (22). In the study by Islam et al (2019), half (50%, 3/6) of the six different brands of antibiotics failed assay and/or dissolution (23).

Ciprofloxacin was the most commonly (67%, 4/6) evaluated antibiotic in all six studies. In three of these studies, the ciprofloxacin samples were substandard with out-of-specification dissolution profiles.

The link between AMR and SF medicine was investigated by Islam et al (2019), as one arm of a three-part study investigating resistance of selected bacteria to commonly used antibiotics and compliance. Even though half the samples failed one of the two tests for quality, the authors commented that products were generally of sufficient quality and that AMR should not be attributed to SF antimicrobials, but to the low rates (18%, n=300) of patients' compliance.



**Post-marketing surveillance:** The MQDB and MQMG, as at the time of the study, did not hold records of any poor-quality antimicrobial from Bangladesh, apart from a WHO Alert on falsified oral cholera vaccine circulating in Bangladesh on MQMG.

We found no current reports from the DGDA's website. In 2011, Bangladesh reported a failure rate of 0.04% of medicines assessed for quality as part of its pharmacovigilance activities (24).

## **Discussion**

In this study, we reviewed regulatory medicine quality assurance policies, media and post-marketing surveillance reports as well as antimicrobial quality studies in Bangladesh to provide an understanding of the local context and to suggest approaches to regulatory system strengthening. This assessment of the integrity of the antimicrobial supply chain in Bangladesh highlights the existence of regulations but a significant knowledge gap on the extent of SF antimicrobials. At the same time, it also highlights innovations and existing structures that could be leveraged to improve regulatory oversight in Bangladesh.

### **Policy provisions, enforcement, and regulatory capacity challenges**

This analysis shows that all iterations of the Bangladesh NDP recognize the need to ensure medicine quality throughout the supply chain and emphasize the need for manufacturers to fully comply with the WHO GMP guidelines. This is in consonance with other countries who have also incorporated these guidelines in their quality assurance mechanisms (25). The NDP also includes GDP guidelines for storage conditions as well as GPP guidelines.

In enforcing the drug laws, Bangladesh leverages other players including security and justice personnel. There is a standing Rapid Action Battalion (RAB) composed of DGDA personnel and

security operatives assisted by a legislative vehicle, the Mobile Court, both to ensure implementation of existing regulations and to impose summary penalties, conducting post-marketing surveillance; similar to Nigeria (26,27).

However, there are regulatory capacity challenges. Overall, regulatory staff strength remains limited with 3,700 staff to oversee a supply chain with some estimated 200,000 distribution points and a product register of some 50,000 generics (28). In 2020, the DGDA maintains offices in only 47 out of the 64 districts of Bangladesh, indicative of structural challenges (18,29). These challenges are similar for other LMICs, including the world's largest generics manufacturer, India (30,31).

### **Market surveillance and medicine quality issues**

Bangladesh, in addition to meeting 98% of its pharmaceutical needs, exports medicines to over a hundred countries (32,33). Its annual pharmaceutical exports is expected to cross the \$1 billion mark in the next two years (34). Recently, the country produced its own remdesivir in a demonstration of its pharmaceutical manufacturing capacity (35).

Our analysis suggests some challenges with the antimicrobial supply chain in Bangladesh for the study period 2017-2020. Indeed, ever since the first report of poor-quality medicine in the 1980s of contaminated paracetamol, there has been recurrent reports in the newspapers of actions by RAB involving SF medicines – mostly falsified products or expired drugs (36–44).

The reports we described above found in the mass media are complemented by laboratory studies we identified from our literature review investigating the quality of antibiotics in circulation in Bangladesh and exploring the impact or implications. The findings are troubling considering that

the evaluated antibiotics are among the top 10 most common licensed in Bangladesh  
(Unpublished results).

Despite the variability in choice of official reference – BP/USP – and methodological challenges with sample sizes, reporting styles, and authors perceptions/views of the implications of study findings, these studies point to the presence of SF antibiotics in the supply chain.

However, while the mass media and medicine quality studies suggest the persistence of SF medicines for human use, the extent of the challenge is not fully understood. In a dated report from 2011, Bangladesh reported a low SF prevalence of <1%. In 2019, the Consumer Protection Agency (CPA) survey estimated a high prevalence of expired medicines in pharmacies and medicine outlets in Bangladesh at 90% (n=600) (45).

### **Developments, knowledge and implementation gaps, and suggestions for regulatory strengthening**

These quality issues which persist in the presence of technically appropriate policies are syndromic of low regulatory capacity and call for improvements in regulatory systems. While there is evidence that this is already happening, for instance in technical analytical capacity, more is needed. In March 2020, the National Control Laboratory of the DGDA received WHO accreditation, two years after it attained the ISO/IEC 17025:2017 accreditation for laboratory testing and calibration (46). The NMRA has received assistance from the USP Pre-Qualification of Medicines (PQM) program to build capacity for the quality assurance of medicines manufactured and distributed in Bangladesh (47). In 2019, it received six Mini-Labs™, portable medicine quality testing devices capable of semi-quantitative analysis for rapid screening of medicine quality during post-marketing surveillance activities (48). However, there are other

capacity challenges to medicine quality assurance of antimicrobials for human and veterinary use, apart from infrastructural, including human resources (29,49).

There is also need for a comprehensive evidence base on the prevalence and spatial distribution of SF antimicrobials to guide targeted and effective regulatory actions using this limited regulatory force. The government, or development partners, could commission a nation-wide quality audit of selected most consumed or marketed antimicrobials available for sale to the public. This would help to identify possible hot-spots for the manufacture, entry, distribution, or sale of SF antimicrobials for a risk-based approach to medicine quality assurance.

Bangladesh could address existing policy implementation gaps and further strengthen the integrity of the antibiotic supply chain by three approaches. Firstly, the use of existing community-based structures as a tool to strengthening medicine quality assurance. Interestingly, there are NGOs advocating for stricter actions on SF medicines, signifying public awareness and concern. For example, the Organization of Social and Environment Changes instituted a suit against the government in 2015 at the High Court questioning government's apparent inaction to control the production of counterfeit medicines (50). These organizations may be leveraged to help with inspections of demand points, especially in hard-to-reach rural areas where SF medicines tend to proliferate, using a checklist created by the DGDA. This checklist which would be based on visual analysis by package inspection could include product licensing status and expiry date. Similar checklists have been proposed and studied (51,52). They could also help create community awareness on SF medicines. Interventions utilizing community-based approaches to improving health outcomes have been demonstrated in Bangladesh for reproductive health and TB management, for examples (53,54). Thus, this strategy could be a useful tool to explore in the context of pharmacovigilance and regulatory inspections.

Secondly, task-shifting approaches using designated academic institutions performing regular surveys on behalf of the DGDA may be another way to expand capacity. To strengthen output measures among several different research institutions, the WHO Guidelines on the conduct of Medicine Quality Assurance Survey could be adopted for uniformity in methodology and reporting (55). Mandating such independent analyses to be shared with the NMRA could provide synergies to improve the integrity of the supply chain in LMICs. While we found that the Bangladesh NDP mentions the use of third-party medicine quality assessors, the extent to which this is utilized to complement efforts by the DGDA within Bangladesh is not known. Task-shifting has been widely used to address workforce capacity challenges in the health sector in many different countries, including high-income settings (56). There may be the need to extend pharmacovigilance also to the veterinary sector, using veterinarians and para veterinarians in the first instance to flag any suspected poor-quality veterinary medicines for follow-up action by the DGDA. The establishment of a separate veterinary medicines agency as is the case with Ethiopia may be another approach at capacity building (57).

Thirdly, scaling up existing technology platforms could lead to synergistic increases in overall regulatory capacity. Recently, as an extension of the national pharmacovigilance system, the DGDA launched a mobile Drug Verification application in 2019 for direct (voluntary) reporting by the public of adverse drug reactions, including of suspected counterfeit medicines (58,59). Mandating all antibiotic manufacturers to include Mobile Authentication Service (MAS) codes on antibiotic packs would complement the Bangladeshi government initiative to enforce the sale of antibiotics only in packages, among others, as a means of promoting appropriate use. This track and trace approach is in use in different forms in countries and regions such as Dubai, Turkey, India and the European Union (60–65). Bangladesh under an innovative a2i project is

leveraging information technology and a >80% mobile phone ownership in its population to provide services to the public. Track and trace technologies already exist in its significant fisheries/aquatic livestock sector (66). Thus, leveraging on a combination of end-user participation and technology could be one approach to improving supply chain integrity.

## **Conclusions**

This study found the existence of regulation and regulatory actions against poor-quality antimicrobials as well as news reports and peer-reviewed studies on poor-quality antimicrobials, but no current rigorous assessment of the extent of poor-quality antimicrobials. We suggest a multi-pronged diffuse approach to regulatory system strengthening comprising three strategies: community-based surveillance, task-shifting, and technology-enabled consumer participation. These approaches could expand capacity to provide a more robust surveillance of the antimicrobial supply chain.

**Funding:** None

**Competing interests:** None declared

**Ethical approval:** Not required (as the study included only document and literature review and was not human subject related, there was no need for ethics).

**Acknowledgment:** This work was made possible by support from the Boston University Social Innovation on Drug Resistance (SIDR) Postdoctoral Program to ESFO.

## References

1. Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ, Jr, et al. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. *BMJ* [Internet]. 1995 Jul 8 [cited 2020 May 11];311(6997):88. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550149/>
2. Geiling EMK, Cannon PR. PATHOLOGIC EFFECTS OF ELIXIR OF SULFANILAMIDE (DIETHYLENE GLYCOL) POISONING: A CLINICAL AND EXPERIMENTAL CORRELATION: FINAL REPORT. *J Am Med Assoc* [Internet]. 1938 Sep 3 [cited 2020 May 11];111(10):919–26. Available from: <https://jamanetwork.com/journals/jama/fullarticle/282251>
3. O'Brien KL, Selanikio JD, Hecdivert C, Placide M-F, Louis M, Barr DB, et al. Epidemic of Pediatric Deaths From Acute Renal Failure Caused by Diethylene Glycol Poisoning. *JAMA* [Internet]. 1998 Apr 15 [cited 2020 May 11];279(15):1175–80. Available from: <https://jamanetwork.com/journals/jama/fullarticle/187441>
4. Brent J. Lessons Learned From Yet Another Episode of Diethylene Glycol Poisoning: It Happened Before and It Happened Again. *JAMA Intern Med* [Internet]. 2014 Jun 1 [cited 2020 May 11];174(6):918–9. Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1868531>
5. Fatal Poisoning Among Young Children from Diethylene Glycol-Contaminated Acetaminophen --- Nigeria, 2008--2009 [Internet]. [cited 2020 May 11]. Available from: <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5848a2.htm>

6. 'Killer cough syrup' maker failed quality tests several times | India News - Times of India [Internet]. The Times of India. [cited 2020 Jun 18]. Available from: <https://timesofindia.indiatimes.com/india/killer-cough-syrup-maker-failed-quality-tests-several-times/articleshow/74262228.cms>
7. WHO | A study on the public health and socioeconomic impact of substandard and falsified medical products [Internet]. WHO. [cited 2020 Feb 4]. Available from: <http://www.who.int/medicines/regulation/ssffc/publications/se-study-sf/en/>
8. Ozawa S, Haynie DG, Bessias S, Laing SK, Ngamasana EL, Yemeke TT, et al. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo. *Am J Trop Med Hyg* [Internet]. 2019 May 1 [cited 2019 Sep 23];100(5):1149–57. Available from: <http://www.ajtmh.org/content/journals/10.4269/ajtmh.18-0334>
9. Sprenger M. Global Action Plan on Antimicrobial Resistance: DRIVE AB Presentation - Setting the Scene [Internet]. [cited 2020 Feb 4]. Available from: [http://drive-ab.eu/wp-content/uploads/2017/09/Marc-Sprenger\\_Global-AMR-PDF-Protected.pdf](http://drive-ab.eu/wp-content/uploads/2017/09/Marc-Sprenger_Global-AMR-PDF-Protected.pdf)
10. Nwokike J, Clark A, Nguyen PP. Medicines quality assurance to fight antimicrobial resistance. *Bull World Health Organ* [Internet]. 2018 Feb 1;96(2):135–7. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29403117>
11. WHO. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products [Internet]. 2017 [cited 2019 Dec 25]. Available from: <https://apps.who.int/iris/bitstream/handle/10665/326708/9789241513425-eng.pdf?ua=1>
12. WHO. Delivering Quality-Assured medical Products for All 2019-2023: WHO's five-year plan to help build effective and efficient regulatory systems (WHO/MVP/RHT/2019.01)



[Internet]. 2019 [cited 2020 Jun 17]. Available from:

[http://158.232.12.119/medicines/news/2019/WHO\\_ActionPlanWeb.pdf](http://158.232.12.119/medicines/news/2019/WHO_ActionPlanWeb.pdf)

13. Laws and Policies [Internet]. [cited 2020 May 11]. Available from:

<https://www.dgda.gov.bd/index.php/laws-and-policies>

14. WHO. Assessment of medicines regulatory systems in sub-Saharan African countries: An overview of findings from 26 assessment reports [Internet]. 2010 [cited 2020 Jun 17]. Available from: [https://www.who.int/healthsystems/Assessment26African\\_countries.pdf?ua=1](https://www.who.int/healthsystems/Assessment26African_countries.pdf?ua=1)

15. U.S Pharmacopoeial Convention (USP). Strengthening Regulatory Systems To Improve Medical Product Quality in Low- and Middle-Income Countries: Promoting the Quality of Medicines (PQM) program [Internet]. 2018 [cited 2020 Jun 18]. Available from:

<https://www.usp->

[pqm.org/sites/default/files/pqms/article/strengtheningregulatorysystemsforqa\\_sept2018.pdf](https://www.usp-pqm.org/sites/default/files/pqms/article/strengtheningregulatorysystemsforqa_sept2018.pdf)

16. Global Health - Medicines Quality Database | USP [Internet]. [cited 2020 May 27].

Available from: <https://www.usp.org/global-public-health/medicines-quality-database>

17. First global tool to track news reports of substandard and falsified medical products is live — CTMGH [Internet]. [cited 2020 May 28]. Available from:

<https://www.tropicalmedicine.ox.ac.uk/news/first-global-tool-to-track-news-reports-of-substandard-and-falsified-medical-products-is-live>

18. Home [Internet]. [cited 2020 Mar 19]. Available from: <http://www.dgda.gov.bd/>

19. Fake medicine factories busted | The Daily Star [Internet]. [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/fake-medicine-factories-busted-41167>

20. Fake medicine factory busted [Internet]. The Daily Star. 2014 [cited 2020 Apr 9]. Available from: <https://www.thedailystar.net/fake-medicine-factory-busted-32701>
21. Faruque A, Ononna HF, Al Hossain AM, Ganguly A. Potency Determination of Essential Drug Samples Manufactured By Medium and Small Pharmaceutical Industries in Bangladesh. Bangladesh Med Res Counc Bull [Internet]. 2018 Jan 4 [cited 2019 Jun 14];43(2):87–93. Available from: <https://www.banglajol.info/index.php/BMRCB/article/view/35195>
22. Uddin MS, Mamun AA, Hossain MS, Asaduzzaman M, Sarwar MS, Rashid M, et al. In vitro quality evaluation of leading brands of ciprofloxacin tablets available in Bangladesh. BMC Res Notes [Internet]. 2017 May 30;10(1):185–185. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28558832>
23. Islam MS, Sikdar KYK, Hossain AMA, Faroque ABM. Study on the Pattern of Antibiotic Use Including the Resistance Episodes in Bangladesh. Dhaka Univ J Pharm Sci [Internet]. 2019 Sep 22 [cited 2020 May 18];18(2):135–43. Available from: <https://www.banglajol.info/index.php/JPharma/article/view/43255>
24. Nwokike J, Ludeman E, Thumm M. Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries. 2013;144. Available from: <https://apps.who.int/medicinedocs/documents/s21335en/s21335en.pdf>
25. WHO | Good Manufacturing Practices [Internet]. WHO. World Health Organization; [cited 2020 May 11]. Available from: [http://www.who.int/biologicals/vaccines/good\\_manufacturing\\_practice/en/](http://www.who.int/biologicals/vaccines/good_manufacturing_practice/en/)
26. NAFDAC. COUNTERFEIT-AND-FAKE-DRUGS-AND-UNWHOLESOME-PROCESSED-FOODS-Cap.-C.34.pdf [Internet]. 2020 [cited 2020 Aug 4]. Available from:

[https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Regulations/NAFDAC\\_Acts/COUNTERFEIT-AND-FAKE-DRUGS-AND-UNWHOLESOME-PROCESSED-FOODS-Cap.-C.34.pdf](https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Regulations/NAFDAC_Acts/COUNTERFEIT-AND-FAKE-DRUGS-AND-UNWHOLESOME-PROCESSED-FOODS-Cap.-C.34.pdf)

27. Nigeria leads in fight against fake drugs - NAFDAC DG [Internet]. Vanguard News. 2011 [cited 2020 Aug 4]. Available from: <https://www.vanguardngr.com/2011/07/nigeria-leads-in-fight-against-fake-drugs-nafdac-dg/>
28. DGDA. Allopathic Drug Database [Internet]. [cited 2020 Feb 16]. Available from: <https://dgda.gov.bd/index.php/manufacturers/allopathic>
29. Hassan MR. Challenges of Good Governance for Medicine in Bangladesh: The Directorate of Drug Administration. :20.
30. Kadam AB, Maigetter K, Jeffery R, Mistry NF, Weiss MG, Pollock AM. Correcting India’s Chronic Shortage of Drug Inspectors to Ensure the Production and Distribution of Safe, High-Quality Medicines. *Int J Health Policy Manag* [Internet]. 2016 Apr 27 [cited 2020 Jun 18];5(9):535–42. Available from: [http://ijhpm.com/article\\_3190.html](http://ijhpm.com/article_3190.html)
31. Agnihotri S, Chandrashekar S. DRUG REGULATION IN INDIA. :55.
32. Express TF. “Bangladesh exports medicines to 151 countries” [Internet]. The Financial Express. [cited 2020 Jun 18]. Available from: <https://thefinancialexpress.com.bd/trade/bangladesh-exports-medicines-to-151-countries-1530964162>
33. Bangladesh pharmaceutical industry blooms bigger [Internet]. Dhaka Tribune. 2019 [cited 2020 Apr 11]. Available from:

<https://www.dhakatribune.com/business/2019/08/22/bangladesh-pharmaceutical-industry-blooms-bigger>

34. 'Bangladesh's annual pharma export to cross \$1bn in 2 years' [Internet]. The Business Standard. 2020 [cited 2020 Jun 18]. Available from:

<https://tbsnews.net/economy/trade/bangladeshs-annual-pharma-export-cross-1bn-2-years-49303>

35. First generic remdesivir will be sold by Bangladesh drug maker [Internet]. STAT. 2020 [cited 2020 Jun 18]. Available from: <https://www.statnews.com/pharmalot/2020/05/22/gilead-remdesivir-covid19-coronavirus-beximco-patent/>

36. Shaon AI. Fake drug factory busted in Dhaka [Internet]. Dhaka Tribune. 2014 [cited 2020 Feb 4]. Available from: <https://www.dhakatribune.com/uncategorized/2014/12/08/fake-drug-factory-busted-in-dhaka>

37. Ahmed MF. Checking Fake Medicine. The Daily Star [Internet]. 2019 Jan 5 [cited 2020 Mar 19]; Available from: <https://www.thedailystar.net/backpage/news/minilabs-six-districts-1683232>

38. Fake medicines seized, two jailed [Internet]. The Daily Star. 2019 [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/country/news/fake-medicines-seized-two-jailed-1800391>

39. Fake medicine factory busted in Noakhali | The Daily Star [Internet]. [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/country/fake-medicine-factory-busted-noakhali-1558102>

40. Fake medicine factory busted in Khulna, two sent to jail | The Daily Star [Internet]. [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/city/fake-medicine-factory-busted-khulna-two-sent-jail-1297834>
41. Rab seizes counterfeit drugs worth Tk 6 crore | The Daily Star [Internet]. [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/city/news/rab-seizes-counterfeit-drugs-worth-tk-6-crore-1801642>
42. Cache of date-expired medicines seized: Rab [Internet]. The Daily Star. 2018 [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/city/news/cache-date-expired-medicines-seized-rab-1657051>
43. 34 medicine stores fined Tk 56 lakh in Old Dhaka [Internet]. The Daily Star. 2018 [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/city/34-medicine-stores-fined-taka-56-lakh-in-old-dhaka-1610491>
44. Mitford medicine shops kept shut [Internet]. The Daily Star. 2013 [cited 2020 Apr 9]. Available from: <https://www.thedailystar.net/news/mitford-medicine-shops-kept-shut>
45. Pharmacies to be tried under Special Powers Act if adulterated medicines found twice: HC [Internet]. The Business Standard. 2019 [cited 2020 Apr 1]. Available from: <https://tbsnews.net/bangladesh/court/pharmacies-be-tried-under-special-powers-act-if-adulterated-medicines-are-found>
46. Directorate of drug admin lab gets WHO accreditation [Internet]. The Daily Star. 2020 [cited 2020 Apr 7]. Available from: <https://www.thedailystar.net/city/news/directorate-drug-admin-lab-gets-who-accreditation-1880044>

47. robel.haliu@usp.org. Bangladesh Implements Updated Standards for Medicines Testing [Internet]. 2019 [cited 2020 Apr 7]. Available from: <https://www.usp-pqm.org/results/bangladesh-success-story>
48. Mini-labs in six districts [Internet]. The Daily Star. 2019 [cited 2020 Apr 13]. Available from: <https://www.thedailystar.net/backpage/news/minilabs-six-districts-1683232>
49. Ahmed SM, Naher N, Hossain T, Rawal LB. Exploring the status of retail private drug shops in Bangladesh and action points for developing an accredited drug shop model: a facility based cross-sectional study. J Pharm Policy Pract [Internet]. 2017 Dec [cited 2020 Mar 25];10(1):1–12. Available from: <https://jopp.biomedcentral.com/articles/10.1186/s40545-017-0108-8>
50. HC questions govt failure to stop fake drugs [Internet]. The Daily Star. 2015 [cited 2020 Apr 9]. Available from: <https://www.thedailystar.net/country/hc-questions-govt-failure-stop-fake-drugs-84013>
51. Barojas A. The Three-Level Approach: A Framework for Ensuring Medicines Quality in Limited-Resource Countries. Pharm Regul Aff Open Access [Internet]. 2014 [cited 2019 Oct 4];03(01). Available from: <http://www.omicsgroup.org/journals/the-threelevel-approach-a-framework-for-ensuring-medicines-quality-in-limitedresource-countries-2167-7689.1000117.php?aid=24068>
52. B S, E W, V M, J V der E, B DS, R R. A simplified checklist for the visual inspection of finished pharmaceutical products: a way to empower frontline health workers in the fight against poor-quality medicines [Internet]. Vol. 13, Journal of pharmaceutical policy and practice. J

Pharm Policy Pract; 2020 [cited 2020 Aug 4]. Available from:

<https://pubmed.ncbi.nlm.nih.gov/32377348/>

53. Reiss, Keenan, Church, Dijkerman, Mitu, Nuremowla, et al. Drug Seller Provision Practices and Knowledge of Misoprostol in Bangladesh. *Int Perspect Sex Reprod Health* [Internet]. 2019 [cited 2020 May 28]; 45:45. Available from:

<https://www.jstor.org/stable/10.1363/45e7819>

54. Daru P, Matji R, AlMossawi HJ, Chakraborty K, Kak N. Decentralized, Community-Based Treatment for Drug-Resistant Tuberculosis: Bangladesh Program Experience. *Glob Health Sci Pract* [Internet]. 2018 Oct 3 [cited 2020 May 28];6(3):594–602. Available from:

<http://www.ghspjournal.org/lookup/doi/10.9745/GHSP-D-17-00345>

55. Guidelines on the Conduct of Surveys of the Quality of Medicines. WHO Technical Report Series, No. 996, 2016, Annex 7 [Internet]. [cited 2020 Mar 10]. Available from:

<https://apps.who.int/medicinedocs/en/m/abstract/Js22404en/>

56. de Maeseneer J, Bourek A, McKee M, Barry M, Brouwer W, Kringos DS, et al. Task Shifting and Health System Design: Report of the Expert Panel on effective ways of investing in Health (EXPH). European Union; 2019.

57. Veterinary Drug and Animal Feed Administration and Control Authority of Ethiopia. Veterinary Drug and Animal Feed Administration & Control Authority [Internet]. 2020 [cited 2020 Mar 16]. Available from: <http://www.vdfaca.gov.et/>

58. Chevaux T. National Guideline on the Pharmacovigilance System in Bangladesh | SIAPS Program [Internet]. [cited 2020 Apr 8]. Available from:

<http://siapsprogram.org/publication/national-guideline-on-the-pharmacovigilance-system-in-bangladesh/>

59. DGDA Drug Verification for Android - APK Download [Internet]. APKPure.com. [cited 2020 Feb 19]. Available from: <https://apkpure.com/dgda-drug-verification/com.dgda.adr>

60. Rasheed H, Höllein L, Holzgrabe U. Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries. *Front Pharmacol* [Internet]. 2018 Aug 31 [cited 2020 Feb 4]; 9:995. Available from: <https://www.frontiersin.org/article/10.3389/fphar.2018.00995/full>

61. Sinha AK. Indian government implements track and trace system for pharmaceuticals [Internet]. 2018 [cited 2020 Jun 18]. Available from: <https://gs1india.org/media/dava-case-study.pdf>

62. ABPI: The Association of the British Pharmaceutical Industry. Falsified Medicines Directive (FMD) | ABPI [Internet]. 2020 [cited 2020 Feb 4]. Available from: <https://www.abpi.org.uk/new-medicines/supply-chain/falsified-medicines-directive-fmd/>

63. Dhillon AA. Track and Trace: Indian Pharma – Current and Future Applicability – *MedicinMan* [Internet]. 2019 [cited 2020 Jun 18]. Available from: <https://medicinman.net/2019/07/track-and-trace-indian-pharma-current-and-future-applicability/>

64. admin\_iracm. Dubai: Dubai to implement comprehensive medicine track and trace system in 2020 - [Internet]. [cited 2020 Jun 18]. Available from: <https://www.iracm.com/en/2020/01/dubai-dubai-implement-comprehensive-medicine-track-trace-system-2020/>



65. SmartTrack. SmartTrack – An advanced pharmaceutical tracking solution for a better healthcare ecosystem [Internet]. 2020 [cited 2020 Jun 18]. Available from: <http://smarttrack.ae/>
66. Islam M, Rahman M, Haque M. Strength and weakness of existing traceability system of seafood production in Bangladesh. *Progress Agric.* 2017;11.
67. Silva RB da, Mattos CA de. Critical Success Factors of a Drug Traceability System for Creating Value in a Pharmaceutical Supply Chain (PSC). *Int J Environ Res Public Health* [Internet]. 2019 Jun 4;16(11):1972. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31167350>
68. Date expired medicine in community clinics [Internet]. *The Daily Star.* 2016 [cited 2020 Apr 11]. Available from: <https://www.thedailystar.net/editorial/date-expired-medicine-community-clinics-195709>
69. Rahman MdM, Asraful M, Haque, Nahian F, Fahim. COMPARATIVE QUALITY EVALUATION OF DIFFERENT BRANDS OF CIPROFLOXACIN TABLETS AVAILABLE IN PHARMACEUTICAL MARKET OF BANGLADESH. 2019 Apr 30; Vol I:43–9.
70. Hasin F, Hossain MM, Ghosh MK, Paul S, Rahman M, Ahmad MF. Pharmaceutical Quality evaluation of Cefuroxime axetil tablets available in drug market of Bangladesh. *World J Pharm Pharm Sci.* 2017;7(1):1589–99.
71. Noor S, Salam FBA, Hima HN, Bhuiyan S, Chowdhury S. Comparative in-vitro quality evaluation of some brands of Metronidazole tablet available in Bangladesh. *Int J Appl Res.* 2017;3(7):753–8.

72. Newspaper 24 Live. English Newspaper | List of all English Newspapers of Bangladesh [Internet]. [cited 2020 Apr 11]. Available from: <https://www.24livenewspaper.com/english-newspaper>

*Table 1 Framework for assessing the regulatory policy document of Bangladesh as adapted from WHO and USP, grouping 10 regulatory functions under four regulatory mechanisms covering all supply chain elements (14,15).*

<b>Supply chain element(s)</b>	<b>Regulatory mechanism</b>	<b>Regulatory functions</b>
Manufacturers and importers	Current Good Manufacturing Practice (cGMP) requirements	(i) marketing authorization or registration, including labelling requirements (ii) licensing (iii) inspection (iv) quality control (v) clinical trials and generics equivalency tests (vi) compliance
Distributors	Good Distribution Practices (GDP)	(vii) GDP
Demand points	Good Pharmacy Practice (GPP) guidelines for appropriate use	(viii) Prescription only sales of antibiotics (Pharmacies and medicine outlets) & Standard Treatment Guidelines (Hospitals, and other healthcare facilities)

---

	(ix) Licensing of persons (competency to own medicine outlets) as well of the premise
All	Pharmacovigilance and market surveillance (x) Market surveillance activities

---

Notes: These regulatory functions are not intended to suggest the full complement of regulatory activities of any NMRA. For example, we did not evaluate provisions for control of advertising/promotion. However, they encompass the five main functions performed by NMRA as listed by the WHO, including marketing authorization, licensing, inspection, quality control and pharmacovigilance; as well as seven out of eight key functions as listed by the USP (14,15)

**Table 2 Policy provision of selected relevant regulatory mechanisms for the five tiers or elements in the antimicrobial/medicine supply chain. (Numbers in brackets are the exact sections of the BNDP.)**

<b>Tier</b>	<b>Mechanism(s)</b>	<b>Policy provision for medicine quality assurance in the National Drug Policy, 2016</b>
<b>Primary manufacturer (API)</b>	cGMP, inspection of manufacturers, compliance with standards and regulatory reliance <sup>1</sup> .	Registration only for competent manufacturers meeting WHO GMP guidelines. Imports (only for certain medicines) need to comply with registration requirements of the USA, UK, Germany, France, Switzerland, Japan, and Australia for human medicines; and, in addition to these countries, the EU, Canada, South Korea and Singapore for veterinary medicines. The policy authorizes inspection of manufacturing premises for compliance with GMP. APIs are expected to comply with relevant pharmacopeial standards.
<b>Secondary manufacturer (FPP)</b>	Quality control laboratory for medicine testing	The establishment and use of medicine quality testing laboratories at the National and Divisional levels by the DGDA (the National Control Laboratories), as well as collaborations with the Bangladesh Council of Scientific and Industrial Research. Additionally, it recognizes other public, private, or autonomous research organizations as third-party quality evaluators (3.12).
	cGMP training	Continuous GMP training for both manufacturers and inspectors

	Clinical trials and generic equivalence	Creation of public and private sector clinical trials and bio-equivalence study facilities (3.19)
	Product labelling	GMP manufacturing and proper labelling of veterinary medicines to guide use & prevent misuse (4.26).
	Environmental protection <sup>2</sup>	Effluent Treatment Plants by all pharmaceutical manufacturers in addition to relocation to non-residential areas to prevent environmental pollution
	Audit	Self-audits by pharmaceutical manufacturers using DGDA prepared checklists.
<b>Wholesale Distributor</b>	GDP	Formulation of a Good Distribution Practices guideline by the DGDA (4.8c)
<b>Local Distributor</b>		
<b>Demand point</b>	GPP <sup>3</sup> : Prescription only sale of antimicrobials	Prohibition of sale and distribution of drugs without prescription from registered physicians/veterinaries, except for OTC drugs (3.14; 4.3g; 4.18). The OTC list contains only three antimicrobials: two antihelminth (albendazole, mebendazole) and one antibiotic (metronidazole).
	GPP: Supervision under competent persons	Drug sale and distribution to be under the direct supervision of professional pharmacists (4.3d)  Pharmacies to be operated only under the supervision of registered physicians or pharmacists; and for all other distribution points

---

including private drug storage facilities and hospital-pharmacies to be under the supervision of pharmacists registered by the Bangladesh Pharmacy Council (4.8e).

---

GPP: Formularies, Standard Treatment Guidelines and Drugs Therapeutic Committees for rational use	Formularies, which should be publicly available, both nationally and individually at all hospitals, to guide rational use, as well as operationalization of “Hospital Pharmacies” under the direct & supervision of hospital pharmacists (4.3b&d) and Mandating public and private hospitals with $\geq 100$ beds to have an antibiotic use guideline; to be followed by similar guidelines for all types of hospitals (4.3b) for “Drugs and Therapeutic committee to be formed in all public and private hospitals to ensure rational use of drugs including antibiotics”
---	--

---

<b>All tiers</b>	Pharmacovigilance	Pharmacovigilance at demand points, drug manufacturers, drug marketing organizations, and patients (4.13)
------------------	-------------------	---

- 
1. Regulatory reliance is a mechanism whereby one national MRA accepts products licensed in countries with stringent MRAS without the requirement for additional product registration in-country.
  2. Not an integral function of MRAs. However, this mechanism is informed by AMR containment strategies.
  3. Good Pharmacy Practices (GPP) considered together as one distinct mechanism.

**Table 3 Newspaper reports of SF antimicrobials**

<b>Date</b>	<b>Title of Facility report (Ref.)</b>	<b>Location</b>	<b>SF category</b>	<b>Source</b>	<b>Therapeutic category</b>	<b>Use</b>
<b>1</b> 1/2/2016	Date expired medicine in community clinics (68)	Community clinics	Sadar Upazilla, Nilphamari	Expired	Public	Anthelmintic Human
<b>2</b> 9/11/2014	Fake medicine factories busted (19)	Factory, warehouses	Amir Market, Mitford, Dhaka Factory Kushiarbagh, Keraniganj	Spurious, fake	N/A	Antibiotics and others
<b>3</b> 7/10/2014	Fake medicine factory busted (20)	Factory	Topkhana, Dhaka	Spurious, fake	Supplier to Mitford	Antibiotics

Note: N/A – Not stated



**Table 4 Reports of quality of antimicrobials in circulation in Bangladesh, 2017-2020**

Study	Source of samples	Brand information (Name and manufacturer)	Name of antibiotic	Dosage form	Number of samples (generic brands)	Samples meeting specifications (%)		Qualitative comments by authors
						Assay	Dissolution	
<b>Islam et al., 2019 (23)</b>	Various locations across Bangladesh	Anonymized	Azithromycin	Tablet	6	100	100 (4/4)	Product quality satisfactory; AMR should not be attributed to SF antimicrobials.
			Ciprofloxacin	Tablet	6	83	83	
			Amoxicillin	Tablet	4	100	100	
			Cefixime	Tablet	7	86	83 (5/6)	
			Cefuroxime	Tablet	5	100	83	
<b>Rahman-Mizanur</b>	Retail pharmacies, Dhaka	No	Ciprofloxacin	Tablet	5	100	100	Products of quality

---

**et al.,**  
**2019 (69)**

---

<b>Faruque</b>	Rural areas	Anonymized	Cefixime	7	Nil	N/A	Substandard
<b>et al.,</b>	of different		Cephradine	6	Nil		drugs in
<b>2018 (21)</b>	Upazillas of		Ciprofloxacin	6	Nil		circulation
	Dhaka,		Metronidazole	7	Nil		produced by
	Jamalpur,		Amoxicillin	6	Nil		some small and
	Faridpur,		Azithromycin	7	43%		middle
	Magura,						industries.
	Pirojpur,						
	Barisal,						
	Chandpur,						
	Rangpur,						
	Habiganj						
	and						
	Chittagong						

---

<b>Hasin et al., 2017 (70)</b>	Drug store, Dhaka	Anonymized	Cefuroxime axetil	Tablet	3	100	100	Pharmaceutically and physiologically equivalent.
<b>Noor et al., 2017 (71)</b>	Drug stores, Dhaka	Anonymized	Metronidazole	Tablet	9	100	100	Almost all brands were of quality.
<b>Uddin et al., 2017 (22)</b>	Retail pharmacies, Dhaka	Yes	Ciprofloxacin	Tablet	10	100	40 (BP); 60 (USP)	The need to focus on quality, rather than marketing.

Notes: BP = British Pharmacopoeia; USP = United States Pharmacopoeia; N/A = Not assessed; SF = Substandard and Falsified; AMR = Antimicrobial Resistance

## Appendix

Market surveillance and quality issues: To map reports of SF medicines and market surveillance activities, we conducted a combined literature and database review as detailed:

Literature review for reports on SF medicines: The search strategy is as described:

Google was searched for “online Bangladesh English language newspapers”, retrieving 21 (72). Of these, that with the largest print circulation – the Daily Star – was purposively selected. The search term was “medicine”. Following a preliminary scan to identify local descriptors of poor-quality medicines, headlines/titles/captions and “abstracts”, or “one-liners” were then searched for any containing the following keywords: “fake”, “adulterated”, “substandard”, “closure”, “illegal”, “counterfeit”, “unwholesome”, “banned” or “expired”. Reports meeting these criteria were assessed for eligibility. Inclusion criteria were antimicrobial(s)/ antibiotic/ antihelminth(ic). Editorials and commentary pieces were excluded. Also excluded were reports on non-allopathic medicines including herbal and homeopathic medicines. Data was extracted in the form of the following variables: facility type (manufacturer, hospital or medicine outlet, trader, other) where SF medicines were found; location of facility; category of SF medicine; and whether medicine indicated for use in human or animals. Data were entered into an Excel spreadsheet for analysis.

Reporting on quality testing:

BANGLAJOL: The search on Banglajol was conducted using the search terms “medicine quality” and “drug quality”. Titles were screened for the same key words used in the literature search on Google above in addition to “quality”. Exclusion criteria were any study outside Bangladesh, studies on non-pharmaceutical substances including food and water.

EMBASE: The search on EMBASE was limited to publication year including 2016-2020 and filtered by drug. All antimicrobials used in human and animal health were selected.

GOOGLE SCHOLAR: The search on Google Scholar was limited from 2016-date; patents and citations were excluded before performing the search on Google Scholar. Search was conducted on May 18-19, 2020. The search term was “drug quality Bangladesh”. Retrieved articles were screened for relevance. Titles and abstracts containing “quality” AND/OR “Bangladesh” and describing a laboratory analysis were collated into a reference manager software. Laboratory analyses were identified by any, or combinations of, the following terms: “*in vitro*”, “HPLC”, “dissolution”, “potency”, “assay”, “pharmacopeial”, “evaluation”, “analysis”, or “release”.

Articles were then assessed for eligibility for evaluation using the following criteria:

- Inclusion: Only articles describing a laboratory analysis of an antibiotic were evaluated.
- Exclusions: Studies conducted outside of Bangladesh studies; studies on method development without comments on medicine quality; quality studies on diagnostic or clinical care; articles describing prevalence or incidence without primary data on compendial analysis; studies on other therapeutics groups not including antibiotics. Data extracted included: Facility type and location from which samples were collected; name of samples, where a sample was one antimicrobial agent identified by the International Non-proprietary Name (INN), number of samples (brands), official tests, and proportions of samples passing the tests. To ensure comparability, data was collected only for two official tests – potency (assay) and dissolution. The qualitative comments of authors in the discussion section of the articles were noted to gauge overall perceptions. Any article linking poor-quality to AMR was noted.